Jump Financial’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.6M Buy
+579,882
New +$18.7M 0.18% 103
2026
Q1
Sell
-12,583
Closed -$443K 2436
2025
Q4
$443K Sell
12,583
-290,141
-96% -$10.3M 0.01% 1372
2025
Q3
$7.96M Sell
302,724
-157,691
-34% -$4.7M 0.09% 269
2025
Q2
$12.2M Buy
+460,415
New +$12.1M 0.13% 197
2025
Q1
Sell
-93,372
Closed -$3.76M 2054
2024
Q4
$3.76M Buy
+93,372
New +$5.32M 0.08% 333
2024
Q3
Sell
-6,594
Closed -$350K 2155
2024
Q2
$350K Buy
+6,594
New +$432K 0.01% 1316
2024
Q1
Sell
-33,837
Closed -$630K 2333
2023
Q4
$630K Sell
33,837
-148,600
-81% -$1.94M 0.02% 936
2023
Q3
$2.02M Buy
+182,437
New +$2.61M 0.07% 365
2023
Q1
Sell
-56,800
Closed -$534K 2095
2022
Q4
$534K Sell
56,800
-3,200
-5% -$14.3K 0.03% 744
2022
Q3
$163K Buy
+60,000
New +$197K 0.01% 1383
2022
Q2
Sell
-55,883
Closed -$168K 2049
2022
Q1
$168K Buy
+55,883
New +$200K 0.01% 1344
2021
Q4
Sell
-10,800
Closed -$68K 1748
2021
Q3
$68K Buy
+10,800
New +$66.7K ﹤0.01% 1015

Other funds holding VKTX

Jump Financial's VKTX Position: Q2 2026 in Review

Jump Financial opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 579,882 shares worth $22.6M. The stake represents 0.18% of the portfolio and ranks #103 among its holdings. This is a return to the name: Jump Financial previously reported a position in VKTX as recently as Q4 2025.

Jump Financial first reported a position in VKTX in Q3 2021 and has held it in 12 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Jump Financial held 579,882 shares of Viking Therapeutics worth $22.6M as of Q2 2026.
  • Viking Therapeutics was a new Jump Financial position in Q2 2026.
  • Viking Therapeutics made up 0.18% of Jump Financial's portfolio in Q2 2026, its #103 holding.
  • Jump Financial first reported a position in Viking Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.